Figure 5: AKT-specific inhibitor MK2206 decreases cell viability, spheroid formation, and migration of SETD2 deficient ccRCCderived cells. (A) Bright-field microscopy images showing living cells (attached to bottom of well) stained with 0.3% crystal violet solution of SETD2 (+/+) 786-0 and SETD2 (KO) 786-0 and (-/-) A498 cells were treated with vehicle (DMSO) or 1 μM AKT-specific inhibitor MK2206 for 10 days. (B) Bar graph showing relative cell viability as a percentage of CTL of SETD2 (+/+) 786-0 and SETD2 (KO) 786-0 and (-/-) A498 cells in response to treatment with MK2206. ****P < 0.0001; ns, no statistical significance observed. Standard deviations were calculated and represented for all conditions. (C) Phase-contrast pictures showing spheroid formation of SETD2 (+/+) 786-0 and SETD2 (KO) 786-0 and (-/-) A498 cells in response to treatment with vehicle (DMSO) and 500 nM inhibitor for 14 days grown in Matrigel. (D) Bar graph showing average colony number of SETD2 (+/+) 786-0 and SETD2 (KO) 786-0 and (-/-) A498 cells treated with MK2206 inhibitor. ****P < 0.0001; ns, no statistical significance observed. Standard deviations were calculated and represented for all conditions. (E) Bright-field microscopy images showing living cells stained with 0.3% crystal violet solution. (F) Bar graph showing percentage (%) of wound closure compared to cells treated with vehicle (DMSO). (G) Western blot analysis of indicated proteins showing variations in phosphorylation levels in response to chemical inhibition with MK2206 (AKT-specific). Whole-cell protein lysates from cells treated with 1 μM inhibitor for 24 hours were resolved by SDS-PAGE. Actin is a loading control.
